Pfenex disclosed last night that it received notice from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority, advising the company of its decision not to exercise development options for cGMP manufacturing and potential Phase 1/2b study readiness for the company’s novel anthrax vaccine candidates Px563L and RPA563, collectively, the anthrax programs. In the notice BARDA stated: “While technical risks were noted, this decision was more of a reflection of the programmatic strategy around [BARDA’s] vaccine portfolio as a whole, and a lack of products for other urgent threats.” Following the receipt of the notice from BARDA and pursuant to ongoing discussions with BARDA, the company “is assessing the priority of this program in its portfolio.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.